Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015:2015:403291.
doi: 10.1155/2015/403291. Epub 2015 Apr 14.

Cardioprotective Activity of Pongamia pinnata in Streptozotocin-Nicotinamide Induced Diabetic Rats

Affiliations

Cardioprotective Activity of Pongamia pinnata in Streptozotocin-Nicotinamide Induced Diabetic Rats

Sachin L Badole et al. Biomed Res Int. 2015.

Abstract

Pongamia pinnata (L.) Pierre has been used in traditional medicine for the treatment for diabetes and metabolic disorder. The aim of this study was to investigate the effect of petroleum ether extract of the stem bark of P. pinnata (known as PPSB-PEE) on cardiomyopathy in diabetic rats. Diabetes was induced in overnight fasted Sprague-Dawley rats by using injection of streptozotocin (55 mg/kg, i.p.). Nicotinamide (100 mg/kg, i.p.) was administered 20 min before administration of streptozotocin. Rats were divided into group I: nondiabetic, group II: diabetic control (tween 80, 2%; 10 mL/kg, p.o.) as vehicle, and group III: PPSB-PEE (100 mg/kg, p.o.). The blood glucose level, ECG, hemodynamic parameters, cardiotoxic and antioxidant biomarkers, and histology of heart were carried out after 4 months after STZ with nicotinamide injection. PPSB-PEE treatment improved the electrocardiographic, hemodynamic changes; LV contractile function; biological markers; oxidative stress parameters; and histological changes in STZ induced diabetic rats. PPSB-PEE (100 mg/kg, p.o.) decreased blood glucose level, improved electrocardiographic parameters (QRS, QT, and QTc intervals) and hemodynamic parameters (SBP, DBP, EDP, max dP/dt, contractility index, and heart rate), controlled levels of cardiac biomarkers (CK-MB, LDH, and AST), and improved oxidative stress (SOD, MDA, and GSH) in diabetic rats. PPSB-PEE is a promising remedy against cardiomyopathy in diabetic rats.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of PPSB-PEE on blood glucose level in rats. Values are mean ± SEM, n = 6 in each group; and statistical analysis was carried out by one-way ANOVA followed by post hoc Dunnett's test performed using GraphPad Prism; ∗∗ p < 0.01; ∗∗∗ p < 0.001; ns: nonsignificant compared with diabetic group; ### p < 0.001; ns: nonsignificant compared with nondiabetic group.
Figure 2
Figure 2
Effect of PPSB-PEE on oxidative stress markers in rats. Values are mean ± SEM, n = 6 in each group; and statistical analysis was carried out by one-way ANOVA followed by post hocDunnett's test performed using GraphPad Prism; ∗∗ p < 0.01, ∗∗∗ p < 0.001 compared with diabetic control group; ### p < 0.001 compared with nondiabetic group.
Figure 3
Figure 3
Effect of PPSB-PEE on histopathology of heart in rats. A-group I: nondiabetic, B-group II: diabetic control (tween 80, 2%; 10 mL/kg, p.o.), and C-group III: PPSB-PEE (100 mg/kg, p.o.). (a) Nondiabetic rat showing normal architecture of heart (Grade − −). (b) Diabetic control rat heart showing massive necrosis of heart muscle fibers along with focal mass and fragmentation (+++). (c) PPSB-PEE (100 mg/kg, p.o.) treated rat heart showing minimum pathological changes, that is, swelling of myocardial fibers and focal degeneration (++). Grade −: no injury; Grade ++++: severe injury; Grade ++: moderate injury (magnification 10x).

References

    1. Maya L., Villarreal F. J. Diagnostic approaches for diabetic cardiomyopathy and myocardial fibrosis. Journal of Molecular and Cellular Cardiology. 2010;48(3):524–529. doi: 10.1016/j.yjmcc.2009.06.021. - DOI - PMC - PubMed
    1. Wang J., Song Y., Wang Q., Kralik P. M., Epstein P. N. Causes and characteristics of diabetic cardiomyopathy. The Review of Diabetic Studies. 2006;3(3):108–117. doi: 10.1900/rds.2006.3.108. - DOI - PMC - PubMed
    1. Zhi Y. F., Prins J. B., Marwick T. H. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocrine Reviews. 2004;25(4):543–567. doi: 10.1210/er.2003-0012. - DOI - PubMed
    1. Kannel W. B., Hjortland M., Castelli W. P. Role of diabetes in congestive heart failure: the Framingham study. The American Journal of Cardiology. 1974;34(1):29–34. doi: 10.1016/0002-9149(74)90089-7. - DOI - PubMed
    1. Boudina S., Abel E. D. Diabetic cardiomyopathy revisited. Circulation. 2007;115(25):3213–3223. doi: 10.1161/CIRCULATIONAHA.106.679597. - DOI - PubMed

MeSH terms